PPS
PAIN PRACTICE SOLUTIONS

Utilizing platelet-rich plasma and amniotic allografts for facet joint intervention in acute Whiplash-Associated Disorders: a pathway to enhanced recovery

How to cite this paper:
O'Connor, D. (2025). Utilizing Platelet-Rich Plasma for Facet Joint Intervention in Acute Whiplash-Associated Disorders: A Pathway to Enhanced Recovery.

Purpose Statement

This white paper evaluates platelet-rich plasma (PRP) and amniotic allograft (AA) injections for facet-joint–mediated whiplash-associated disorder (WAD) after motor-vehicle accidents. It outlines facet-joint pathology, reviews PRP and AA basic science, and summarizes evidence for their role in achieving durable relief.

Executive Summary

PRP and AA show promise for injuries that have plateaued, including facet-mediated pain in WAD. Our clinic's experience mirrors the favorable outcomes reported in the literature reviewed here.

Key Findings

- Cervical facet joints enable motion and rely on ligaments, tendons, synovium, and cartilage for function.
- In Whiplash Associated Disorders (WAD) from Motor Vehicle Accidents (MVAs), facet joints are the leading pain generator.
- WAD can have a poor prognosis with substantial pain and disability.
- PRP concentrates a patient's platelets to promote tissue repair, reduce pain, and restore function.
- AA (derived from amniotic membrane/fluid, umbilical cord, and/or blood) supports tissue healing, pain reduction, and functional recovery.
- Both PRP and AA deliver growth factors that can optimize healing/inflammatory responses, particularly when recovery is limited by injury or baseline health.
- These therapies may recruit pluripotent progenitor ("stem") cells to the injury site, further enhancing repair.
- Studies report pain and functional benefits in spinal conditions, including facet-mediated WAD.
- In our practice, combining standard care with PRP/AA, targeted acute corticosteroid use, and progressive rehabilitation has improved patient trajectories; broader research is still needed.

Implications

Injecting PRP and/or AA into pathological facet joints and related soft tissues may help patients overcome recovery plateaus and avoid poor WAD outcomes. Medico-legal professionals should refer clients to clinicians experienced with these interventions.

Introduction

Whiplash-Associated Disorder (WAD) describes the cluster of symptoms that can follow a motor-vehicle collision (MVA) or similar rapid head–neck acceleration/deceleration.[1,3] Symptoms may involve the neck, jaw, upper/lower back and limbs, and often include headaches, dizziness, concussion-type brain symptoms, and mental-health sequelae.[1,2,4,11] For deeper background, see our white paper, "Whiplash: An In-Depth Review of Pathology and the Biomechanics of Injury."

WAD is difficult to treat given its varied presentations. [12, 13] Cervical facet (zygapophyseal) joints and related soft tissues are frequent pain sources.[14,16] Collision forces (rear, frontal, lateral) can impose multi-directional shear, tension, and compression that exceed tissue tolerance, leading to persistent pain and dysfunction.[17,24]

Clinicians often start with corticosteroid injections to reduce inflammation and pain, [25,28] but benefits may be short, lived and, if overused or misused, can harm tissues.[29–35] Increasing evidence supports platelet-rich plasma (PRP) and amniotic allograft (AA) injections as alternatives for longer-term pain control and functional restoration in neuromusculoskeletal conditions, including WAD.[36,42] This paper reviews PRP and AA for facet-mediated pain and function loss after WAD.

Facet Pathology in WAD After MVA

Cervical facet (zygapophyseal) joints are paired articulations between superior and inferior processes that guide neck motion. [43] They are synovial joints with capsules and articular cartilage for smooth movement and load bearing, and they function with surrounding ligaments and musculotendinous structures. [44] These tissues maintain normal motion but can each generate pain when injured.[15,45,47]

Injury mechanisms by impact type.

- Direction of impact in an MVA shapes the pattern and severity of facet injury.
- Rear impact: Initial cervical retraction/straightening followed by extension creates tensile and compressive loads, commonly affecting lower facets (C4–C7) and upper-cervical ligaments (C1–C2).[48,49,14,15,19,50]
- Frontal impact: Head contact (wheel/windshield/airbag) can shear the cervical spine, often involving facets at C5–C7 and C2/3.[51,19,21,52]
- Lateral impact: Combined rotation and side-bending impose compression and shear across levels; C6/7 often absorbs ipsilateral compression, with C3–C7 exceeding physiologic limits.[23,53,54]

Severity is further influenced by head position at impact, startle reflex, and pre-existing (previously stable) conditions.[55,58] For full biomechanics, see our white paper, "Whiplash: An In-Depth Review of Pathology and the Biomechanics of Injury."

Facets as a primary pain generator

Literature repeatedly identifies facets as the most common WAD pain source.[14,59,63] Reported prevalence's include: 60% (Lord et al.),[61] ≥54% (Barnsley et al.),[62] 60% (Manchikanti et al.),[64] 63% (Aprill & Bogduk),[65] 29% (Persson et al., 2016),[66] and 74% (Gibson et al.).[67]

Economic impact

Poorly managed WAD leads to substantial societal costs. UK estimates cite ~£3.1 billion annually in healthcare and productivity losses,[68] with £99.55–£668.53 per case in the first four months post-injury.[69] Modeling from Sweden suggests that expanding specialized zygapophyseal pain management from 2% to 25% of cases could save ~106 million SEK annually and add 14 quality-adjusted life years.[70]

The Basic Science of Platelet-Rich Plasma (PRP) and of Amniotic Allografts

PRP is an autologous concentration of platelets prepared at supraphysiologic levels to promote tissue healing, reduce pain, and restore function.[71,73] It has shown efficacy across multiple conditions, including knee osteoarthritis, carpal tunnel syndrome, lateral epicondylitis, rotator-cuff disorders, and low-back pain.[73,78] Preparation involves drawing venous blood and centrifuging it to isolate plasma with platelets above baseline.[72] Typical whole-blood counts are 150,000–450,000/μL; PRP is commonly defined as 3–5× that concentration.[72,79] Sub-types include leukocyte-rich PRP, leukocyte-poor PRP, platelet-poor plasma, platelet-rich fibrin, and platelet lysate, each suited to specific indications.[80,83]

How PRP works

PRP releases high levels of growth factors and proteins that accelerate the healing cascade in otherwise slow-to-heal tissues.[84] Following injury, platelets drive hemostasis and regeneration via factors such as VEGF, EGF, HGF, PDGF, TNF-α, and TGF-β1; higher local concentrations enhance repair.[85],[86],[87],[84],[88] Platelet signaling also recruits pluripotent progenitor ("stem") cells to the injury site, where they can differentiate into tendon, cartilage, muscle, nerve, and bone, among others.[84],[87],[89],[93]

Amniotic Allografts (AA)

AAs are derived from human amniotic tissues (membrane, fluid, umbilical cord/blood) for use in regenerative orthopedics.[94] Processing can yield surgical sheets or injectable particulates while preserving growth factors, proteins, and antimicrobial peptides.[94],[95] AAs provide growth factors, cytokines, and extracellular-matrix components that support repair, modulate immunity, and reduce inflammation, and they can recruit progenitor cells similar to PRP.[94],[96]–[99] Despite being non-autologous, AAs have low immunogenicity, reduced HLA expression and localized suppression of innate/adaptive responses.[100],[101] Clinically, injectable AAs have been used for knee osteoarthritis, ankle/foot tendinosis, degenerative musculoskeletal pain, cartilage defects, hip osteoarthritis, rotator-cuff pathology, lumbar radiculopathy, and facet pathology.[40],[102],[109]

Choosing between PRP and AA

Both are reasonable next-step options when conservative care (therapy, medications, corticosteroid injections) fails. PRP requires venipuncture and on-site processing into the desired formulation before injection (often ~30–60 minutes, depending on equipment).[72] If overall health, PRP quality, venipuncture aversion, or time constraints are concerns, AA—providing concentrated growth factors without on-site blood processing, may be preferable.[110], [112] Shared, pragmatic decision-making should guide selection to optimize outcomes.

Evidence for PRP or AA Use in Facet Joints and their Long-Term Outcomes

After usual care fails to resolve persistent whiplash pain, the cervical facets—often injured in MVAs and frequently responsible for ongoing symptoms, become logical therapeutic targets for biologic interventions.

Early evidence with PRP is encouraging. In a 2023 pragmatic study, patients with chronic, facet-mediated WAD who received PRP, either with usual care or combined with multimodal physiotherapy, showed large to very large reductions in pain, better performance of daily activities, and improvements in disability, psychological measures, and quality of life, without adverse events.[113] A 2025 comparison of leukocyte-poor and leukocyte-rich PRP found that both formulations improved outcomes at 3 and 6 months, with the leukocyte-rich preparation producing greater 6-month gains in pain and disability and no safety signals.[114] Complementary cohort work in 2023 observed clinically meaningful improvements in pain, disability, strength, and mobility when PRP was integrated with physiotherapy, suggesting a synergistic effect.[115]

Single-session injections can also help plateaued patients: in a series of 44 individuals with chronic WAD, ultrasound- and fluoro-guided PRP yielded significant disability and pain reductions; 70% achieved at least minimal pain improvement, 80% achieved at least minimal disability improvement, and 41% reported ≥50% pain relief at three months.[116] In a head-to-head study versus corticosteroid injections, both treatments improved cervical facetogenic pain at 1–6 months, but PRP produced higher pain self-efficacy and less procedural pain—advantages that can facilitate active rehabilitation.[117] Longer-term follow-up from Canada showed durability: among patients selected by a positive medial branch block, 53% exceeded the MCID for pain at 12 months after PRP (mean 66% improvement on the NPRS), and 69% exceeded the MCID on the NDI.[118] Even at the elite level, a case report of an Olympic pole-vaulter described 60% relief after the second of three PRP injections and complete pain resolution with unrestricted training by six months.[119]

Amniotic allografts show similarly promising signals. In a prospective study of 40 patients, average pain dropped from 6.4/10 at baseline to 2.7 at one month, 1.7 at two months, and 1.4 at three months; 91% achieved clinically meaningful (≥30%) improvements, with no adverse events.[42] A 2019 spinal-pain cohort reported a 94.6% average pain reduction after a single AA injection, universal discontinuation of prescription analgesics, and no adverse events across six months.[107] Another series administering single AA facet injections documented patient-reported global improvement of ~48% at six weeks, 53.5% at three months, 58.9% at six months, and 56.7% at twelve months, again without adverse events and with ~15-minute procedure times.[108] A retrospective review in patients with long-standing spinal pathology (mean symptom duration 54 ± 63 months) likewise found significant pain reductions and no recorded adverse events.[120]

Overall, the literature indicates that both PRP and AA can deliver clinically meaningful—and often durable—improvements in pain and disability for cervical facet–mediated WAD, with favorable safety profiles. For many patients, PRP's gains in pain self-efficacy may further enhance participation in rehabilitation, while AA offers a time-efficient, non-autologous option when PRP is impractical. [113],[120],[42],[107],[108]

Real-World Application

In practice, patients with WAD and cervical facet–related pain often arrive in a pro-inflammatory state with high pain and disability that blocks participation in active rehab.[121],[123] Yet active interventions are essential for restoring function, work capacity, and daily activities, which pain frequently inhibits.[124],[126] A judicious early corticosteroid injection in the acute to early subacute phase can lower pain enough to start effective therapy and to gauge healing progress, aligning with Jull et al.'s guidance that "early implementation of effective pain management for those with early moderate to high pain levels is critical…to lessen the transition to chronicity."[127]

However, even with steroids onboard, many WAD patients remain symptomatic for years.[127],[128] To change that trajectory, the early steroid should be followed ~2 weeks later by PRP or AA, not by repeated steroid injections to optimize biologic healing at the injured facets and associated soft tissues.[129] This shift is supported both by the positive PRP/AA data and by evidence of deleterious effects from repeated corticosteroid injections on cartilage and other joint structures.[130],[131]

Both PRP and AA deliver concentrated healing signals that can restart stalled repair, reduce pain to enable fuller participation in physical therapy, and improve strength, function, and quality of life with minimal adverse events and typically less procedural discomfort than corticosteroid injections. Taken together, a pragmatic pathway emerges: control early pain to unlock rehab, then transition promptly to PRP or AA to drive tissue recovery, an approach aimed at preventing chronicity and delivering better long-term outcomes for facet-mediated WAD.

Clinical Implications and Future Directions

For WAD, usual care too often falls short. As one review summarizes: "50% of individuals will recover from pain and disability within 3 to 6 months of injury, but the remainder will continue to report symptoms up to 1 to 2 years or longer after the motor vehicle crash. Of those who do not recover, between 30% and 40% are likely to have persistent mild to moderate levels of pain and between 10% and 20% will have moderate to severe pain syndromes." [127]

Against that backdrop, providers should leverage the growing evidence for PRP and AA, which shows favorable outcomes for facet-mediated WAD integrated with sound pain management and active rehabilitation to restore strength and function. [113], [120] Looking ahead, larger retrospective series and randomized controlled trials are warranted to validate what many clinicians in our network observe in daily practice.

Conclusion

Facet pain in the setting of WAD is challenging, and population-level prognosis is poor with standard care. Innovative strategies are needed. Emerging evidence and our clinical experience suggests that PRP and AA for facet pain after WAD can shift patients from persistent disability toward meaningful recovery. [113], [120]

Next Steps

For attorneys seeking optimal outcomes for clients, ensure the care team understands the principles in this white paper. Platelet-Rich Plasma and Amniotic Allograft injections can materially improve facet-related pain and dysfunction in WAD. Direct referral to providers experienced with these interventions may help prevent transition to chronic pain through timely, appropriate management.

References

1. Ghorayeb JH. The nosological classification of whiplash-associated disorder: a narrative review. The Journal of the Canadian Chiropractic Association 2021;65:76.
2. Bannister G, Amirfeyz R, Kelley S, et al. Whiplash injury. The Journal of Bone & Joint Surgery British Volume 2009;91:845-850.
3. Vállez García D, Dierckx RAJO, Otte A, et al. Whiplash, Real or Not Real? A Review and New Concept. PET and SPECT in Neurology, 2014;947-963.
4. Fundaun J, Kolski M, Baskozos G, et al. Nerve pathology and neuropathic pain after whiplash injury: a systematic review and meta-analysis. Pain 2022;163:e789-e811.
5. Fundaun J, Ridehalgh C, Koushesh S, et al. The presence and prognosis of nerve pathology following whiplash injury: a prospective cohort study. Brain 2025:awaf088.
6. Särkilahti N, Leino S, Takatalo J, et al. The symptom profile of people with whiplash-associated disorder–a mixed-method systematic review. Journal of Bodywork and Movement Therapies 2024.
7. Alderink GJ, Ashby BM. Cervical Spine: Lateral Whiplash, Neck Pain, and Nerve Palsy. Clinical Kinesiology and Biomechanics: A Problem-Based Learning Approach: Springer, 2023;145-177.
8. Al-Khazali HM, Ashina H, Iljazi A, et al. Psychiatric sequelae following whiplash injury: a systematic review. Frontiers in psychiatry 2022;13:814079.
9. Kuperman P, Granovsky Y, Fadel S, et al. Head- and neck-related symptoms post-motor vehicle collision (MVA): Separate entities or two-sides of the same coin? Injury 2021;52:1227-1233.
10. Sterling M, Jull G, Vicenzino B, et al. Physical and psychological factors predict outcome following whiplash injury. Pain 2005;114:141-148.
11. Rebbeck T, Evans K, Elliott JM. Concussion in Combination With Whiplash-Associated Disorder May Be Missed in Primary Care: Key Recommendations for Assessment and Management. J Orthop Sports Phys Ther 2019;49:819-828.
12. Griffin AR, Moloney N, Leaver A, et al. Defining recovery in chronic whiplash: a qualitative study. The Clinical Journal of Pain 2020;36:505-515.
13. Walton DM, MacDermid JC, Giorgianni AA, et al. Risk factors for persistent problems following acute whiplash injury: update of a systematic review and meta-analysis. Journal of Orthopaedic & Sports Physical Therapy 2013;43:31-43.
14. Hellinga M, van Eerd M, Stojanovic M, et al. 7. Cervical facet pain: Degenerative alterations and whiplash-associated disorder. Pain Practice 2025;25:e70005.
15. Curatolo M, Bogduk N, Ivancic PC, et al. The role of tissue damage in whiplash-associated disorders: discussion paper 1. Spine 2011;36:S309-S315.
16. Eseonu K, Panchmatia J, Pang D, et al. A Review of the Clinical Utility of Therapeutic Facet Joint Injections in Whiplash Associated Cervical Spinal Pain. Spine Surgery and Related Research 2022;6:189-196.
17. Kohles SS, McClaren JW. A stochastic model validated with human test data causally associating target vehicle Delta V, occupant cervicocranial biomechanics, and injury during rear-impact crashes. Journal of forensic and legal medicine 2022;91:102431.
18. Kaneoka K, Ono K, Inami S, et al. The Human Cervical Spine Motion During Rear-Impact Collisions. Journal of Whiplash & Related Disorders 2011;1:85-97.
19. Pearson AM, Ivancic PC, Ito S, et al. Facet joint kinematics and injury mechanisms during simulated whiplash. Spine 2004;29:390-397.
20. Pearson AM, Panjabi MM, Ivancic PC, et al. Frontal impact causes ligamentous cervical spine injury. Spine 2005;30:1852-1858.
21. Dowdell J, Kim J, Overley S, et al. Biomechanics and common mechanisms of injury of the cervical spine. Handbook of clinical neurology 2018;158:337-344.
22. Shateri H, Cronin DS. Out-of-Position Rear Impact Tissue-Level Investigation Using Detailed Finite Element Neck Model. Traffic Injury Prevention 2015;16:698-708.
23. Shen T-WD. Investigation of Whiplash Associated Disorders using Finite Element Neck Models with Active Musculature in Frontal, Rear and Lateral Impact: University of Waterloo, 2020.
24. Maak TG, Ivancic PC, Tominaga Y, et al. Side impact causes multiplanar cervical spine injuries. Journal of Trauma and Acute Care Surgery 2007;63:1296-1307.
25. Hodgens A, Sharman T. Corticosteroids. StatPearls [Internet]: StatPearls Publishing, 2023.
26. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis & Rheumatism 2001;44:585-574? (as provided: 585-594?).
27. Li H, Xie W, Strong JA, et al. Systemic anti-inflammatory corticosteroid reduces mechanical pain behavior, sympathetic sprouting, and elevation of pro-inflammatory cytokines in a rat model of neuropathic pain. Anesthesiology 2007;107:469.
28. Yang S, Chang MC. The effectiveness of corticosteroid injection into cervical facet joint for managing whiplash-related neck pain. Annals of Palliative Medicine 2022;11:2569-2573.
29. Cauchon A-M, Mares C, Fan XY, et al. Comparing the efficacy of intra-articular injection of Platelet Rich Plasma (PRP) with corticosteroids (CS) in patients with chronic zygapophyseal joint low back pain confirmed by double intra-articular diagnostic blocks: A triple-blinded randomized multicentric controlled trial with a 6-month follow-up. Interventional Pain Medicine 2024;3:100525.
30. Hawkins N, García A, López-Candelas F, et al. Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints—A Systematic Review of the Literature. JAAOS Global Research & Reviews 2025;9:e24.
31. Aleid AM, Alyabis NA, Aldanyowi SN, et al. Efficacy of platelet-rich plasma versus corticosteroid injections in recovery from plantar fasciitis: A systematic review and meta-analysis. Journal of Taibah University Medical Sciences 2025;20:120-128.
32. Peng Y, Li F, Ding Y, et al. Comparison of the effects of platelet-rich plasma and corticosteroid injection in rotator cuff disease treatment: a systematic review and meta-analysis. Journal of Shoulder and Elbow Surgery 2023;32:1303-1313.
33. Stone S, Malanga GA, Capella T. Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain. Pain Physician 2021;24:S233.

34. McGarry JG, Daruwalla ZJ. The efficacy, accuracy and complications of corticosteroid injections of the knee joint. Knee surgery, sports traumatology, arthroscopy 2011;19:1649-1654.
35. Kamel SI, Rosas HG, Gorbachova T. Local and Systemic Side Effects of Corticosteroid Injections for Musculoskeletal Indications. AJR Am J Roentgenol 2024;222:e2330458.
36. Gosens T, Peerbooms JC, van Laar W, et al. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. The American journal of sports medicine 2011;39:1200-1208.
37. Shetty SH, Dhond A, Arora M, et al. Platelet-rich plasma has better long-term results than corticosteroids or placebo for chronic plantar fasciitis: randomized control trial. The Journal of Foot and Ankle Surgery 2019;58:42-46.
38. Dai W-L, Zhou A-G, Zhang H, et al. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Arthroscopy: The Journal of Arthroscopic & Related Surgery 2017;33:659-670.e651.
39. Kia C, Baldino J, Bell R, et al. Platelet-rich plasma: review of current literature on its use for tendon and ligament pathology. Current reviews in musculoskeletal medicine 2018;11:566-572.
40. Gomoll AH, Farr J, Cole BJ, et al. Safety and efficacy of an amniotic suspension allograft injection over 12 months in a single-blinded, randomized controlled trial for symptomatic osteoarthritis of the knee. Arthroscopy: The Journal of Arthroscopic & Related Surgery 2021;37:2246-2257.
41. Ansari A, Baig M, Tanbour Y, et al. Efficacy of Amniotic Suspension Allografts in the Treatment of Knee Osteoarthritis: A Systematic Review. The journal of knee surgery 2025.
42. Gellhorn AC, Han A. The use of dehydrated human amnion/chorion membrane allograft injection for the treatment of tendinopathy or arthritis: a case series involving 40 patients. PM&R 2017;9:1236-1243.
43. Curtis L, Shah N, Padalia D. Facet joint disease. 2019.
44. Bogduk N, Mercer S. Biomechanics of the cervical spine. I: Normal kinematics. Clinical biomechanics 2000;15:633-648.
45. Zhang S, Zhao E, Winkelstein BA. A nociceptive role for integrin signaling in pain after mechanical injury to the spinal facet capsular ligament. Annals of biomedical engineering 2017;45:2813-2825.
46. Stegmann T, Steinke H, Pieroh P, et al. On the importance of the innervation of the human cervical longitudinal ligaments at vertebral level. Surgical and Radiologic Anatomy 2020;42:127-136.
47. Johnson GM. The sensory and sympathetic nerve supply within the cervical spine: review of recent observations. Manual Therapy 2004;9:71-77.
48. Chen H-b, King HY, Wang Z-g. Biomechanics of whiplash injury. Chinese journal of traumatology 2009;12:305-314.
49. Grauer JN, Panjabi MM, Cholewicki J, et al. Whiplash produces an S-shaped curvature of the neck with hyperextension at lower levels. Spine 1997;22:2489-2494.
50. Deng B. Kinematics of human cadaver cervical spine during low-speed rear-end impacts: Wayne State University, 1999.
51. Eid HO, Abu-Zidan FM. Biomechanics of road traffic collision injuries: a clinician's perspective. Singapore medical journal 2007;48:693.
52. Ito S, Ivancic PC, Pearson A, et al. Cervical intervertebral disc injury during simulated frontal impact. European Spine Journal 2005;14:356-365.
53. Maak TG. Dynamic Intervertebral Foramen Narrowing During Whiplash. 2006.
54. Ivancic PC. Mechanisms and mitigation of head and spinal injuries due to motor vehicle crashes. journal of orthopaedic & sports physical therapy 2016;46:826-833.
55. Elliott JM, Noteboom JT, Flynn TW, et al. Characterization of acute and chronic whiplash-associated disorders. journal of orthopaedic & sports physical therapy 2009;39:312-323.
56. Harinathan B, Jebaseelan D, Yoganandan N, et al. Effect of cervical stenosis and rate of impact on risk of spinal cord injury during whiplash injury. Spine 2023;48:1208-1215.
57. Malik K, Eseonu KC, Pang D, et al. Is Preexisting Cervical Degeneration a Risk Factor for Poor Prognosis in Whiplash-Associated Disorder? International Journal of Spine Surgery 2021;15:710-717.
58. Elliott JM, Parrish TB, Walton DM, et al. Does overall cervical spine pathology relate to the clinical heterogeneity of chronic whiplash? The American journal of emergency medicine 2020;38:869-873.
59. Schofferman J, Bogduk N, Slosar P. Chronic whiplash and whiplash-associated disorders: an evidence-based approach. JAAOS-Journal of the American Academy of Orthopaedic Surgeons 2007;15:596-606.
60. Sizer Jr PS, Poorbaugh K, Phelps V. Whiplash associated disorders: pathomechanics, diagnosis, and management. Pain Practice 2004;4:249-266.
61. Lord SM, Barnsley L, Wallis BJ, et al. Chronic cervical zygapophysial joint pain after whiplash: a placebo-controlled prevalence study. Spine 1996;21:1737-1744.
62. Barnsley L, Lord SM, Wallis BJ, et al. The prevalence of chronic cervical zygapophysial joint pain after whiplash. Spine 1995;20:20-25.
63. Bogduk N. On cervical zygapophysial joint pain after whiplash. Spine 2011;36:S194-S199.
64. Manchikanti L, Singh V, Rivera J, et al. Prevalence of cervical facet joint pain in chronic neck pain. Pain Physician 2002;5:243.
65. Aprill C, Bogduk N. The prevalence of cervical zygapophyseal joint pain; a first approximation. Spine 1992;17:744-747.
66. Persson M, Sörensen J, Gerdle B. Chronic whiplash associated disorders (WAD): responses to nerve blocks of cervical zygapophyseal joints. Pain Medicine 2016;17:2162-2175.
67. Gibson T, Bogduk N, Macpherson J, et al. Crash characteristics of whiplash associated chronic neck pain. Journal of Musculoskeletal Pain 2000;8:87-95.
68. Galasko CS, Murray P, Stephenson W. Incidence of whiplash-associated disorder. British Columbia Medical Journal 2002;44:237-240.
69. Pink J, Petrou S, Williamson E, et al. Economic and health-related quality of life outcomes of whiplash associated disorders. Spine 2016;41:1378-1386.
70. Hambraeus J. Interventional pain management focused on zygapophysial joint pain: a health-economic evaluation: Umeå University, 2023.

71. Middleton KK, Barro V, Muller B, et al. Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. The Iowa orthopaedic journal 2012;32:150.
72. Arnoczky SP, Shebani-Rad S. The basic science of platelet-rich plasma (PRP): what clinicians need to know. Sports medicine and arthroscopy review 2013;21:180-185.
73. Shen L, Yuan T, Chen S, et al. The temporal effect of platelet-rich plasma on pain and physical function in the treatment of knee osteoarthritis: systematic review and meta-analysis of randomized controlled trials. Journal of orthopaedic surgery and research 2017;12:16.
74. Senna MK, Shaat RM, Ali AAA. Platelet-rich plasma in treatment of patients with idiopathic carpal tunnel syndrome. Clinical rheumatology 2019;38:3643-3654.
75. Li S, Yang G, Zhang H, et al. A systematic review on the efficacy of different types of platelet-rich plasma in the management of lateral epicondylitis. Journal of Shoulder and Elbow Surgery 2022;31:1533-1544.
76. A. Hamid MS, Sazlina SG. Platelet-rich plasma for rotator cuff tendinopathy: A systematic review and meta-analysis. Plos one 2021;16:e0251111.
77. Xuan Z, Yu W, Dou Y, et al. Efficacy of platelet-rich plasma for low back pain: a systematic review and meta-analysis. Journal of Neurological Surgery Part A: Central European Neurosurgery 2020;81:529-534.
78. Wongjarupong A, Pairuchvej S, Laohapornsvan P, et al. "Platelet-Rich Plasma" epidural injection an emerging strategy in lumbar disc herniation: a Randomized Controlled Trial. BMC Musculoskeletal Disorders 2023;24:335.
79. Straum OK. The optimal platelet concentration in platelet-rich plasma for proliferation of human cells in vitro—diversity, biases, and possible basic experimental principles for further research in the field: A review. PeerJ 2020;8:e10303.
80. Kim J-H, Park Y-B, Ha C-W, et al. Adverse reactions and clinical outcomes for leukocyte-poor versus leukocyte-rich platelet-rich plasma in knee osteoarthritis: a systematic review and meta-analysis. Orthopaedic Journal of Sports Medicine 2021;9:23259671211011948.
81. Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin appendage disorders 2018;4:18-24.
82. Collins T, Alexander D, Barkatali B. Platelet-rich plasma: a narrative review. EFORT open reviews 2021;6:225-235.
83. Ehrenfest DMD, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends in biotechnology 2009;27:158-167.
84. Dos Santos RG, Santos GS, Alkass N, et al. The regenerative mechanisms of platelet-rich plasma: A review. Cytokine 2021;144:155560.
85. Duchesne E, Dufresne SS, Dumont NA. Impact of inflammation and anti-inflammatory modalities on skeletal muscle healing: from fundamental research to the clinic. Physical therapy 2017;97:807-817.
86. Järvinen TA, Järvinen M, Kalimo H. Regeneration of injured skeletal muscle after the injury. Muscles, ligaments and tendons journal 2014;3:337.
87. Etulain J. Platelets in wound healing and regenerative medicine. Platelets 2018;29:556-568.
88. Pineda-Cortel MR, Suarez C, Cabrera J-T, et al. Complexity of Platelet-Rich Plasma: Mechanism of Action, Growth Factor Utilization and Variation in Preparation. Plasmatology 2024;18:26348535241277625.
89. Li H, Usas A, Poddar M, et al. Platelet-rich plasma promotes the proliferation of human muscle derived progenitor cells and maintains their stemness. PloS one 2013;8:e64923.
90. Imai S, Kumagai K, Yamaguchi Y, et al. Platelet-rich plasma promotes migration, proliferation, and the gene expression of scleraxis and vascular endothelial growth factor in paratenon-derived cells in vitro. Sports Health 2019;11:142-148.
91. Xie X, Zhang C, Tuan RS. Biology of platelet-rich plasma and its clinical application in cartilage repair. Arthritis research & therapy 2014;16:204.
92. Fernandes G, Yang S. Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering. Bone Research 2016;4:1-21.
93. Dou X-Y, An M. Advances in the application of platelet-rich plasma in peripheral nerve injuries. Anesthesiology and Perioperative Science 2025;3:1-9.
94. Nakagawa H, Panero AJ, Qin X, et al. Basic science and preclinical evidence for amniotic membrane– derived allografts in orthobiologics. OrthoBiologics: Elsevier, 2025;111-120.
95. Bedewy N, Elbordiny M, Swelem M, et al. Biochemical assessment of amniotic membrane extract for optimal application in regenerative medicine. Alexandria Journal of Medicine 2024;60:215-221.
96. Maan ZN, Rennert RC, Koob TJ, et al. Cell recruitment by amnion chorion grafts promotes neovascularization. Journal of Surgical Research 2015;193:953-962.
97. Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. International wound journal 2013;10:493-500.
98. Massee M, Chinn K, Lei J, et al. Dehydrated human amnion/chorion membrane regulates stem cell activity in vitro. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2016;104:1495-1503.
99. Moreno SE, Massee M, Koob TJ. Dehydrated human amniotic membrane inhibits myofibroblast contraction through the regulation of the tgfβ-SMAD pathway in vitro. JID Innovations 2021;1:100020.
100. Magatti M, Vertua E, Cargnoni A, et al. The immunomodulatory properties of amniotic cells: the two sides of the coin. Cell transplantation 2018;27:31-44.
101. Wassmer C-H, Berishvili E. Immunomodulatory properties of amniotic membrane derivatives and their potential in regenerative medicine. Current diabetes reports 2020;20:31.
102. Natali S, Farinelli L, Screpis D, et al. Human amniotic suspension allograft improves pain and function in knee osteoarthritis: a prospective not randomized clinical pilot study. Journal of Clinical Medicine 2022;11:3295.
103. McIntyre JA, Jones IA, Danilkovich A, et al. The placenta: applications in orthopaedic sports medicine. The American journal of sports medicine 2018;46:234-247.
104. Hou W-H, Lin P-C, Tung K-M, et al. Effectiveness of amnion allograph injections in patients with degenerative musculoskeletal diseases: a systematic review and meta-analysis. American Journal of Physical Medicine & Rehabilitation 2024:10.1097.

105. Aratikatla A, Maffulli N, Rodriguez HC, et al. Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review. Biomedicines 2022;10:3173.
106. Ackley JF, Kolosky M, Gurin D, et al. Cryopreserved amniotic membrane and umbilical cord particulate matrix for partial rotator cuff tears: A case series. Medicine 2019;98:e16569.
107. Bennett DS. Cryopreserved amniotic membrane and umbilical cord particulate for managing pain caused by facet joint syndrome: a case series. Medicine 2019;98:e14745.
108. Castellanos R. Injectable amniotic membrane/umbilical cord particulate for facet joint syndrome: A retrospective, single-center study. Journal of Back and Musculoskeletal Rehabilitation 2022;35:559-564.
109. Miedema M, Anderson A. Outcomes of transforaminal epidural injection of amniotic membrane/umbilical cord particulate for lumbar radiculopathy: a case series. Frontiers in Pain Research 2024;5:1322848.
110. Argut SK, Celik D, Ergin ON, et al. Factors affecting the features of platelet-rich plasma in patients with knee osteoarthritis. Acta Orthopaedica et Traumatologica Turcica 2023;57:148.
111. Rossi L, Ranalletta M, Pasqualini I, et al. Substantial variability in platelet-rich plasma composition is based on patient age and baseline platelet count. Arthroscopy, Sports Medicine, and Rehabilitation 2023;5:e853-e858.
112. Chowdhary K, Sahu A, Iijima H, et al. Aging affects the efficacy of platelet-rich plasma treatment for osteoarthritis. American Journal of Physical Medicine & Rehabilitation 2023;102:597-604.
113. Smith AD, Gupta AT, Stone J, et al. The Safety and Efficacy of Multimodal Physiotherapy versus Usual Care in Chronic Whiplash-Associated Disorders with Facet-Mediated Pain Undergoing Platelet Rich Plasma (PRP) Treatment: A Series of Single Case Experimental Designs (SCEDs). Interventional Pain Medicine 2023;2:100222.
114. Allison DJ, Loh E, Burnham R, et al. Leukocyte poor platelet rich plasma vs leukocyte rich platelet rich plasma as a treatment for cervical facetogenic pain: A pooled analysis. Interventional Pain Medicine 2025;4:100566.
115. Smith AD, Andruski B, Deng G, et al. Cervical Spine Platelet-Rich Plasma and Physiotherapy Increases Cervical Mobility and Isometric Strength in Chronic Whiplash Associated Disorder. Interventional Pain Medicine 2023;2:100362.
116. Smith A, Andruski B, Deng G, et al. Cervical facet joint platelet-rich plasma in people with chronic whiplash-associated disorders: A prospective case series of short-term outcomes. Interventional Pain Medicine 2022;1:100078.
117. Allison DJ, Ebrahimzadeh S, Muise S, et al. Intra-articular corticosteroid injections versus platelet-rich plasma as a treatment for cervical facetogenic pain: a randomized clinical trial. Regional Anesthesia & Pain Medicine 2024.
118. Smith A, Andruski B, Deng G, et al. Cervical facet joint platelet-rich plasma in people with chronic whiplash-associated disorders: A prospective case series of longer term 6-and 12-month outcomes. Interventional Pain Medicine 2023;2:100237.
119. Aufiero D, Vincent H, Sampson S, et al. Regenerative injection treatment in the spine: review and case series with platelet rich plasma. J Stem Cells Res. Rev & Rep 2015;2:1019.
120. Ross A, Gambrill V, Main C. Clinical outcomes of amniotic membrane/umbilical cord particulate in spinal disorders: A retrospective study. Journal of Pain Research 2022:3971-3979.
121. Stenneberg MS, Scholten-Peeters GG, den Uil CS, et al. Clinical characteristics differ between patients with non-traumatic neck pain, patients with whiplash-associated disorders, and pain-free individuals. Physiotherapy Theory and Practice 2022;38:2592-2602.
122. Stenneberg MS, Rood M, de Bie R, et al. To what degree does active cervical range of motion differ between patients with neck pain, patients with whiplash, and those without neck pain? A systematic review and meta-analysis. Archives of Physical Medicine and Rehabilitation 2017;98:1407-1434.
123. Anstey R, Kongsted A, Kamper S, et al. Are people with whiplash-associated neck pain different from people with nonspecific neck pain? Journal of Orthopaedic & Sports Physical Therapy 2016;46:894-901.
124. Vassiliou T, Kaluza G, Putzke C, et al. Physical therapy and active exercises–an adequate treatment for prevention of late whiplash syndrome?: Randomized controlled trial in 200 patients. Pain 2006;124:69-76.
125. Scholten-Peeters GG, Bekkering GE, Verhagen AP, et al. Clinical practice guideline for the physiotherapy of patients with whiplash-associated disorders. Spine 2002;27:412-422.
126. Blanpied PR, Gross AR, Elliott JM, et al. Neck pain: revision 2017: clinical practice guidelines linked to the international classification of functioning, disability and health from the orthopaedic section of the American Physical Therapy Association. Journal of Orthopaedic & Sports Physical Therapy 2017;47:A1-A83.
127. Jull GA, Söderlund A, Stemper BD, et al. Toward Optimal Early Management After Whiplash Injury to Lessen the Rate of Transition to Chronicity. Spine 2011;36:S335-S342.
128. Park D. The Pathophysiology and Mechanism of Acute and Chronic Whiplash Injury: A Narrative Review. International Journal of Pain 2022;13:20-24.
129. Dickson RR, Reid JM, Nicholson WT, et al. Corticosteroid and cortisol serum levels following intra-articular triamcinolone acetonide lumbar facet joint injections. Pain Practice 2018;18:864-870.
130. Bharadwaj UU, Lynch JA, Joseph GB, et al. Intra-articular Knee Injections and Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative. Radiology 2025;315:e233081.
131. Ayub S, Kaur J, Hui M, et al. Efficacy and safety of multiple intra-articular corticosteroid injections for osteoarthritis—a systematic review and meta-analysis of randomized controlled trials and observational studies. Rheumatology 2021;60:1629-1639.

